Doximity Dividenden en inkoop

Dividend criteriumcontroles 0/6

Doximity heeft geen dividenduitkeringen gedaan.

Belangrijke informatie

n/a

Dividendrendement

1.6%

Terugkoop Rendement

Totaal aandeelhoudersrendement	1.6%
Toekomstig dividendrendement	0%
Dividendgroei	n/a
Volgende betaaldatum dividend	n/a
Ex-dividenddatum	n/a
Dividend per aandeel	n/a
Uitbetalingsratio	n/a

Recente updates van dividend en inkoop

Recent updates

Doximity: Strong Fundamentals And Growth Potential Makes It Attractive

Dec 06

Doximity (NYSE:DOCS) Knows How To Allocate Capital

Dec 01

Earnings Not Telling The Story For Doximity, Inc. (NYSE:DOCS) After Shares Rise 34%

Nov 13

Does This Valuation Of Doximity, Inc. (NYSE:DOCS) Imply Investors Are Overpaying?

Nov 02

There's Reason For Concern Over Doximity, Inc.'s (NYSE:DOCS) Massive 27% Price Jump

Aug 18

Doximity (NYSE:DOCS) Looks To Prolong Its Impressive Returns

Aug 10

Doximity Faces Slower Revenue Growth As R&D Costs May Rise

Jul 23

Is Doximity, Inc. (NYSE:DOCS) Trading At A 23% Discount?

Jul 23

At US$27.97, Is It Time To Put Doximity, Inc. (NYSE:DOCS) On Your Watch List?

Jul 01

Optimistic Investors Push Doximity, Inc. (NYSE:DOCS) Shares Up 26% But Growth Is Lacking

Jun 09

Doximity Earnings: Better Than Expected, But Still Mixed Outlook (Rating Upgrade)

May 17

Capital Allocation Trends At Doximity (NYSE:DOCS) Aren't Ideal

May 04

Doximity: Significant Upside Remains, But Not Until The Growth Story Returns

Apr 29

With Doximity, Inc. (NYSE:DOCS) It Looks Like You'll Get What You Pay For

Apr 16

Estimating The Fair Value Of Doximity, Inc. (NYSE:DOCS)

Mar 26

Doximity: Rating Upgrade To Buy As Outlook Turns Positive

Feb 21

We Like Doximity's (NYSE:DOCS) Earnings For More Than Just Statutory Profit

Feb 15

What Is Doximity, Inc.'s (NYSE:DOCS) Share Price Doing?

Feb 13

Doximity: Downside Is Contained, While Upside Depends On Management's Game Plan

Jan 16

Doximity (NYSE:DOCS) May Have Issues Allocating Its Capital

Jan 04

Doximity Earnings: Steer Clear Of This Rollercoaster War Of Optimism Vs. Skepticism

Nov 10

Doximity: Adding Value Using AI But Faces Near-Term Risks

Nov 01

Doximity: Rating Downgrade As Investors Shift Focus To The Near-Term Outlook

Aug 24

Doximity Earnings: Too Many Problems, Sell

Aug 09

Doximity: Continue To See Positive Upside From Current Stock Level

Jul 05

Doximity: Digital Health Play With Strong Fundamentals

Jun 21

Doximity: Good Business But Extremely Overvalued

Feb 18

Doximity Q3 Earnings: Disappointing Results

Feb 10

Stabiliteit en groei van betalingen

Dividenden ophalen

Stabiel dividend: Er zijn onvoldoende gegevens om te bepalen of het dividend per aandeel van DOCS in het verleden stabiel is geweest.

Groeiend dividend: Er zijn onvoldoende gegevens om te bepalen of de dividendbetalingen van DOCS zijn gestegen.

Dividendrendement versus markt

Doximity Dividendrendement versus markt

Hoe verhoudt DOCS dividendrendement zich tot de markt?
Segment	Dividendrendement
Bedrijf (DOCS)	n/a
Markt onderkant 25% (US)	1.5%
Markt Top 25% (US)	4.5%
Gemiddelde industrie (Healthcare Services)	0.9%
Analist prognose (DOCS) (tot 3 jaar)	0%

Opmerkelijk dividend: Het dividendrendement van DOCS kan niet worden vergeleken met dat van de onderste 25% van de dividendbetalers, aangezien het bedrijf geen recente uitbetalingen heeft gerapporteerd.

Hoog dividend: Het dividendrendement van DOCS kan niet worden vergeleken met dat van de top 25% van de dividendbetalers, aangezien het bedrijf geen recente uitbetalingen heeft gerapporteerd.

Winstuitkering aan aandeelhouders

Verdiendekking: Er zijn onvoldoende gegevens om de payout ratio DOCS te berekenen en vast te stellen of de dividendbetalingen worden gedekt door de winst.

Contante uitbetaling aan aandeelhouders

Kasstroomdekking: De duurzaamheid van het dividend kan niet worden berekend, omdat DOCS geen uitbetalingen heeft gerapporteerd.

Ontdek bedrijven met een sterk dividend

Bedrijfsanalyse en status van financiële gegevens

Gegevens	Laatst bijgewerkt (UTC-tijd)
Bedrijfsanalyse	2025/01/02 06:36
Aandelenkoers aan het einde van de dag	2025/01/02 00:00
Inkomsten	2024/09/30
Jaarlijkse inkomsten	2024/03/31

Gegevensbronnen

De gegevens die gebruikt zijn in onze bedrijfsanalyse zijn afkomstig van S&P Global Market Intelligence LLC. De volgende gegevens worden gebruikt in ons analysemodel om dit rapport te genereren. De gegevens zijn genormaliseerd, waardoor er een vertraging kan optreden voordat de bron beschikbaar is.

Pakket	Gegevens	Tijdframe	Voorbeeld Amerikaanse bron ^*
Financiële gegevens bedrijf	10 jaar	Resultatenrekening Kasstroomoverzicht Balans	SEC-formulier 10-K SEC-formulier 10-Q
Consensus schattingen analisten	+3 jaar	Financiële prognoses Koersdoelen analisten	Onderzoeksrapporten van analisten Blue Matrix
Marktprijzen	30 jaar	Aandelenprijzen Dividenden, splitsingen en acties	ICE Marktgegevens SEC-formulier S-1
Eigendom	10 jaar	Top aandeelhouders Handel met voorkennis	SEC-formulier 4 SEC-formulier 13D
Beheer	10 jaar	Leiderschapsteam Raad van bestuur	SEC-formulier 10-K SEC-formulier DEF 14A
Belangrijkste ontwikkelingen	10 jaar	Bedrijfsaankondigingen	SEC-formulier 8-K

^* voorbeeld voor effecten uit de VS, voor niet-Amerikaanse effecten worden gelijkwaardige regelgevingsformulieren en bronnen gebruikt.

Tenzij anders vermeld zijn alle financiële gegevens gebaseerd op een jaarperiode, maar worden ze elk kwartaal bijgewerkt. Dit staat bekend als Trailing Twelve Month (TTM) of Last Twelve Month (LTM) gegevens. Lees hier meer.

Analysemodel en Snowflake

Details van het analysemodel dat is gebruikt om dit rapport te genereren, zijn beschikbaar op onze Github-pagina. We hebben ook handleidingen voor het gebruik van onze rapporten en tutorials op Youtube.

Leer meer over het team van wereldklasse dat het Simply Wall St-analysemodel heeft ontworpen en gebouwd.

Industrie en sector

Onze industrie- en sectormetrics worden elke 6 uur berekend door Simply Wall St, details van ons proces zijn beschikbaar op .

Bronnen van analisten

Doximity, Inc. wordt gevolgd door 25 analisten. 19 van deze analisten hebben de schattingen van de omzet of winst ingediend die zijn gebruikt als input voor ons rapport. Inzendingen van analisten worden de hele dag door bijgewerkt.

Analist	Instelling
Vikram Kesavabhotla	Baird
Nisala Weerasuriya	Berenberg
Allen Lutz	BofA Global Research

Doximity Dividenden en inkoop

Dividend criteriumcontroles 0/6

Belangrijke informatie

Recente updates van dividend en inkoop

Doximity, Inc. (NYSE:DOCS) announces an Equity Buyback for $500 million worth of its shares.

Doximity, Inc. (NYSE:DOCS) announces an Equity Buyback for $70 million worth of its shares.

Doximity, Inc. (NYSE:DOCS) announces an Equity Buyback for $200 million worth of its shares.

Recent updates

Now 24% overvalued after recent price rise

Doximity: Strong Fundamentals And Growth Potential Makes It Attractive

Doximity (NYSE:DOCS) Knows How To Allocate Capital

Investor sentiment improves as stock rises 20%

Chief Financial Officer notifies of intention to sell stock

Earnings Not Telling The Story For Doximity, Inc. (NYSE:DOCS) After Shares Rise 34%

Second quarter 2025 earnings: EPS and revenues exceed analyst expectations

Doximity, Inc. Provides Earnings Guidance for Its Fiscal Third Quarter Ending December 31, 2024 and Updating Earnings Guidance for Its Fiscal Year Ending March 31, 2025

Independent Director notifies of intention to sell stock

Does This Valuation Of Doximity, Inc. (NYSE:DOCS) Imply Investors Are Overpaying?

Doximity, Inc. to Report Q2, 2025 Results on Nov 07, 2024

Price target increased by 8.5% to US$37.21

Is Doximity, Inc. (NYSE:DOCS) Potentially Undervalued?

Doximity: Downgrade To Hold On Valuation Concerns

Here's Why Doximity (NYSE:DOCS) Has Caught The Eye Of Investors

Now 22% overvalued after recent price rise

There's Reason For Concern Over Doximity, Inc.'s (NYSE:DOCS) Massive 27% Price Jump

Investor sentiment improves as stock rises 39%

Chief Financial Officer exercised options and sold US$1.1m worth of stock

Price target increased by 7.1% to US$31.64

Doximity (NYSE:DOCS) Looks To Prolong Its Impressive Returns

New minor risk - Share price stability

First quarter 2025 earnings: EPS and revenues exceed analyst expectations

Doximity, Inc. Provides Revenue Guidance for the Second Quarter Ending September 30, 2024 and Fiscal Year Ending March 31, 2025

Doximity Faces Slower Revenue Growth As R&D Costs May Rise

Is Doximity, Inc. (NYSE:DOCS) Trading At A 23% Discount?

Doximity, Inc., Annual General Meeting, Aug 29, 2024

Doximity, Inc. to Report Q1, 2025 Results on Aug 08, 2024

Now 29% undervalued

Now 28% undervalued

At US$27.97, Is It Time To Put Doximity, Inc. (NYSE:DOCS) On Your Watch List?

Now 22% undervalued after recent price drop

Chief Financial Officer notifies of intention to sell stock

Optimistic Investors Push Doximity, Inc. (NYSE:DOCS) Shares Up 26% But Growth Is Lacking

Investor sentiment improves as stock rises 18%

Doximity, Inc. Provides Financial Guidance for the First Quarter Ending June 30, 2024 and Full Year Ending March 31, 2025

Full year 2024 earnings released: EPS: US$0.78 (vs US$0.58 in FY 2023)

Doximity Earnings: Better Than Expected, But Still Mixed Outlook (Rating Upgrade)

Doximity, Inc. (NYSE:DOCS) announces an Equity Buyback for $500 million worth of its shares.

Capital Allocation Trends At Doximity (NYSE:DOCS) Aren't Ideal

Doximity: Significant Upside Remains, But Not Until The Growth Story Returns

Doximity, Inc. to Report Q4, 2024 Results on May 16, 2024

Kessler Topaz Meltzer & Check, LLP Files Securities Fraud Class Action Lawsuit Against Doximity, Inc

With Doximity, Inc. (NYSE:DOCS) It Looks Like You'll Get What You Pay For

Estimating The Fair Value Of Doximity, Inc. (NYSE:DOCS)

Doximity: Rating Upgrade To Buy As Outlook Turns Positive

We Like Doximity's (NYSE:DOCS) Earnings For More Than Just Statutory Profit

What Is Doximity, Inc.'s (NYSE:DOCS) Share Price Doing?

Third quarter 2024 earnings: EPS and revenues exceed analyst expectations

Doximity, Inc. Provides Earnings Guidance for the Fourth Quarter and Full Year Ending March 31, 2024

Price target increased by 7.2% to US$28.17

Doximity, Inc. to Report Q3, 2024 Results on Feb 08, 2024

Doximity: Downside Is Contained, While Upside Depends On Management's Game Plan

Doximity (NYSE:DOCS) May Have Issues Allocating Its Capital

Now 21% undervalued

Investor sentiment improves as stock rises 24%

Doximity, Inc. Provides Revenue Guidance for the Fiscal Third Quarter Ending December 31, 2023 and Fiscal Year Ending March 31, 2024

Second quarter 2024 earnings: EPS and revenues exceed analyst expectations

Doximity, Inc. (NYSE:DOCS) announces an Equity Buyback for $70 million worth of its shares.

Doximity Earnings: Steer Clear Of This Rollercoaster War Of Optimism Vs. Skepticism

Doximity Launches Docdefender, Expanding Services to Safeguard Physician Privacy

Doximity: Adding Value Using AI But Faces Near-Term Risks

Doximity, Inc. to Report Q2, 2024 Results on Nov 09, 2023

Insufficient new directors

Price target decreased by 11% to US$26.91

Doximity: Rating Downgrade As Investors Shift Focus To The Near-Term Outlook

Investor sentiment deteriorates as stock falls 31%

Price target decreased by 13% to US$32.08

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

Doximity, Inc. Provides Earnings Guidance for the Second Quarter Ending September 30, 2023 and Fiscal Year Ending March 31, 2024

Doximity Earnings: Too Many Problems, Sell

Doximity, Inc. to Report Q1, 2024 Results on Aug 08, 2023